In Phase C, individuals will obtain ABBV-744 and oral navitoclax. In Segment D, individuals will receive ABBV-744 and ruxolitinib. Participants will acquire treatment until eventually disease progression or the participants are unable to tolerate the study drugs. 88 These preclinical studies deliver paradigms for upcoming clinical trials in AML, and https://raelk777bny0.blogoscience.com/profile